13-Mar-2026
No headlines found.
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Globe Newswire (Tue, 10-Mar 4:00 PM ET)
Globe Newswire (Tue, 3-Mar 8:00 AM ET)
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.
As of March 13, 2026, ABOS stock price declined to $3.27 with 391,225 million shares trading.
ABOS has a beta of 1.67, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.13 to the broad based SPY ETF.
ABOS has a market cap of $198.08 million. This is considered a Micro Cap stock.
In the last 3 years, ABOS traded as high as $11.31 and as low as $.86.
The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAC.
ABOS has outperformed the market in the last year with a price return of +168.0% while the SPY ETF gained +21.4%. ABOS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +52.8% and +4.1%, respectively, while the SPY returned -2.6% and -3.5%, respectively.
ABOS support price is $3.10 and resistance is $3.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.
